| Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells S Larochelle, KA Merrick, ME Terret, L Wohlbold, NM Barboza, C Zhang, ... Molecular cell 25 (6), 839-850, 2007 | 283 | 2007 |
| A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression MM Schachter, KA Merrick, S Larochelle, A Hirschi, C Zhang, KM Shokat, ... Molecular cell 50 (2), 250-260, 2013 | 166 | 2013 |
| Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells KA Merrick, S Larochelle, C Zhang, JJ Allen, KM Shokat, RP Fisher Molecular cell 32 (5), 662-672, 2008 | 110 | 2008 |
| Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation KA Merrick, L Wohlbold, C Zhang, JJ Allen, D Horiuchi, NE Huskey, ... Molecular cell 42 (5), 624-636, 2011 | 106 | 2011 |
| MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis L Suarez-Lopez, G Sriram, YW Kong, S Morandell, KA Merrick, ... Proceedings of the National Academy of Sciences 115 (18), E4236-E4244, 2018 | 96 | 2018 |
| A pleiotropic RNA-binding protein controls distinct cell cycle checkpoints to drive resistance of p53-defective tumors to chemotherapy IG Cannell, KA Merrick, S Morandell, CQ Zhu, CJ Braun, RA Grant, ... Cancer cell 28 (5), 623-637, 2015 | 94 | 2015 |
| Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways D Horiuchi, N E. Huskey, L Kusdra, L Wohlbold, KA Merrick, C Zhang, ... Proceedings of the National Academy of Sciences 109 (17), E1019-E1027, 2012 | 91 | 2012 |
| Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbs1 as a Cdk2 substrate in human cells L Wohlbold, KA Merrick, S De, R Amat, JH Kim, S Larochelle, JJ Allen, ... Public Library of Science 8 (8), e1002935, 2012 | 82 | 2012 |
| Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma SM Bronner, KA Merrick, J Murray, L Salphati, JG Moffat, J Pang, ... Bioorganic & Medicinal Chemistry Letters 29 (16), 2294-2301, 2019 | 54 | 2019 |
| Picosecond-resolution fluorescence lifetime imaging microscopy: a useful tool for sensing molecular interactions in vivo via FRET W Zhong, M Wu, CW Chang, KA Merrick, SD Merajver, MA Mycek Optics express 15 (26), 18220-18235, 2007 | 38 | 2007 |
| Putting one step before the other: distinct activation pathways for Cdk1 and Cdk2 bring order to the mammalian cell cycle KA Merrick, RP Fisher Cell Cycle 9 (4), 706-714, 2010 | 22 | 2010 |
| Why minimal is not optimal: Driving the mammalian cell cycle—and drug discovery—with a physiologic CDK control network KA Merrick, RP Fisher Cell cycle 11 (14), 2600-2605, 2012 | 20 | 2012 |
| An RNA damage response network mediates the lethality of 5-FU in clinically relevant tumor types JK Chen, KA Merrick, YW Kong, A Izrael-Tomasevic, G Eng, ED Handly, ... bioRxiv, 2023 | 5 | 2023 |
| A virtual cycle: theory and experiment converge on the exit from mitosis KA Merrick, RP Fisher F1000 biology reports 2, 2010 | 5 | 2010 |
| Discovery of Selective Tertiary Amide Inhibitors of Cyclin-Dependent Kinase 2 (CDK2) M Zeng, JM Grandner, MC Bryan, V Verma, R Larouche-Gauthier, ... ACS Medicinal Chemistry Letters 14 (9), 1179-1187, 2023 | 2 | 2023 |
| Predictive model of palbociclib response reveals indications in which CDK4/6 inhibitor can be a potential combination partner M Hafner, N Dompe, W Zhou, E Lin, M Durrbaum, A Daemen, MR Junttila, ... Cancer Research 79 (13_Supplement), 4410-4410, 2019 | 1 | 2019 |
| An RNA damage response network mediates the lethality of 5-FU in colorectal cancer JK Chen, KA Merrick, YW Kong, A Izrael-Tomasevic, G Eng, ED Handly, ... Cell Reports Medicine 5 (10), 2024 | | 2024 |
| A CRITICAL PROTEIN KINASE CONTROLS INFLAMMATION, WOUND REPAIR, AND CANCER AT SITES OF INFLAMMATION L Suarez-Lopez, X De la Rosa, G Sriram, YW Kong, S Morandell, ... SHOCK 51 (6), 41-42, 2019 | | 2019 |
| Abstract P5-04-26: Identification of preclinical mechanisms driving acquired resistance to endocrine therapy in estrogen-receptor positive (ER+) breast cancer cells C Ong, A Daemen, K Merrick, T O'Brien, L Friedman, G Hatzivassiliou Cancer Research 79 (4_Supplement), P5-04-26-P5-04-26, 2019 | | 2019 |
| Identification of preclinical mechanisms driving acquired resistance to endocrine therapy in estrogen-receptor positive (ER plus) breast cancer cells C Ong, A Daemen, K Merrick, T O'Brien, L Friedman, G Hatzivassiliou CANCER RESEARCH 79 (4), 2019 | | 2019 |
